Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $35.86

Pfizer Inc. (NYSE:PFE) has been assigned an average rating of “Hold” from the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.86.

A number of equities research analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd.

Pfizer Stock Performance

Pfizer stock opened at $27.41 on Monday. The stock’s 50 day simple moving average is $27.61 and its two-hundred day simple moving average is $27.73. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $155.32 billion, a price-to-earnings ratio of -456.83, a PEG ratio of 1.06 and a beta of 0.70. Pfizer has a fifty-two week low of $25.20 and a fifty-two week high of $39.87.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the previous year, the business earned $1.23 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, analysts expect that Pfizer will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were given a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.13%. Pfizer’s payout ratio is -2,800.00%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.